<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003478</url>
  </required_header>
  <id_info>
    <org_study_id>1529</org_study_id>
    <secondary_id>DUMC-1529-01-8R4</secondary_id>
    <secondary_id>DUMC-1363-97-9</secondary_id>
    <secondary_id>DUMC-1409-98-9R1</secondary_id>
    <secondary_id>DUMC-1529-00-8R3</secondary_id>
    <secondary_id>DUMC-1630-99-9R2</secondary_id>
    <secondary_id>DUMC-97112</secondary_id>
    <secondary_id>NCI-5950NS20023</secondary_id>
    <secondary_id>NCI-G98-1471</secondary_id>
    <secondary_id>CDR0000066515</secondary_id>
    <nct_id>NCT00003478</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors</brief_title>
  <official_title>Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing&#xD;
      substances such as radioactive iodine to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects, best way to give, and&#xD;
      best dose of radiolabeled monoclonal antibody and to see how well it works in treating&#xD;
      patients with primary brain tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine which one of two delivery techniques (bolus injection versus microinfusion)&#xD;
           provides the greater distribution volume of iodine I 131 antitenascin monoclonal&#xD;
           antibody 81C6 (I 131 MAb 81C6) administered intratumorally in patients with newly&#xD;
           diagnosed or recurrent malignant primary brain tumors.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of I 131 MAb 81C6 delivered intratumorally in these&#xD;
           patients.&#xD;
&#xD;
        -  Evaluate the efficacy of I 131 MAB 81C6 delivered intratumorally in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, dose-escalation study.&#xD;
&#xD;
      Patients are randomized to receive iodine I 131 antitenascin monoclonal antibody 81C6 (I 131&#xD;
      MAb 81C6) by one of two delivery techniques first, then crossover to receive the antibody by&#xD;
      the other technique 3 days later. Each patient then receives a therapeutic dose by the most&#xD;
      efficient method. Both methods are delivered via a stereotactically-placed intralesional&#xD;
      catheter.&#xD;
&#xD;
        -  Arm I: Bolus injection method&#xD;
&#xD;
        -  Arm II: Microinfusion delivery method Cohorts of 3-6 patients receive escalating doses&#xD;
           of I 131 MAb 81C6, with dose escalation occurring separately for each arm. After 10&#xD;
           patients are enrolled and the best method of administration is determined, all&#xD;
           subsequent patients receive I 131 MAb 81C6 by that method, and the maximum tolerated&#xD;
           dose (MTD) is determined. The MTD is defined as the dose at which no more the 2 of 6&#xD;
           patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients with newly diagnosed tumors for which no effective conventional therapy exists, such&#xD;
      as malignant glial tumors, are treated with external beam radiotherapy within 4 months after&#xD;
      I 131 MAb 81C6 infusion. Patients with recurrent tumors receive no other therapy unless tumor&#xD;
      progresses.&#xD;
&#xD;
      Patients are followed at 4, 8, 16, and 24 weeks and then every 12 weeks for one year.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 10 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1997</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody 81C6</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven newly diagnosed or recurrent primary intracranial WHO grade III&#xD;
             or IV glioma&#xD;
&#xD;
          -  Reactivity of tumor cells with 81C6 demonstrated by immunohistology with either a&#xD;
             polyclonal rabbit antibody or the monoclonal mouse antibody&#xD;
&#xD;
          -  Radiographic evidence of a single lesion by MRI or CT scan&#xD;
&#xD;
               -  No greater than 2 to 5 cm&#xD;
&#xD;
          -  No cerebral herniation syndrome&#xD;
&#xD;
          -  Midline brain shift less than 0.5 cm&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase less than 1.5 times normal&#xD;
&#xD;
          -  SGOT less than 1.5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No allergies to iodine or local anesthetics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent autologous bone marrow transplant&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior conventional or phase II chemotherapy regimen&#xD;
&#xD;
          -  No prior phase I chemotherapy regimens&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Corticosteroids allowed but must be on stable dose for at least 1 week&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 months since radiotherapy to site of measurable disease in the nervous&#xD;
             system, unless evidence of progression&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darell D. Bigner, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 15, 2013</last_update_submitted>
  <last_update_submitted_qc>February 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult medulloblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult ependymoblastoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

